Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that?
Small-cell lung cancer (SCLC) has historically been considered a highly chemo-radiosensitive malignancy, rarely susceptible of surgical resection due to advanced stage presentation with bulky nodal disease and frequent systemic involvement. Actually, surgical series documented SCLC in just 2–3% of patients (1) and, although several randomized trials contributed to define the management of extensive and limited stage SCLC, very few data are available for the early stage, possibly resectable, disease.
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? / Ferrara, Roberto; Caccese, Mario; Cuppone, Federica; Bria, Emilio; Tortora, Giampaolo; Pilotto, Sara. - In: TRANSLATIONAL CANCER RESEARCH. - ISSN 2218-676X. - 5:S3(2016), pp. 462-466. [10.21037/tcr.2016.09.09]
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that?
Ferrara, Roberto;
2016-01-01
Abstract
Small-cell lung cancer (SCLC) has historically been considered a highly chemo-radiosensitive malignancy, rarely susceptible of surgical resection due to advanced stage presentation with bulky nodal disease and frequent systemic involvement. Actually, surgical series documented SCLC in just 2–3% of patients (1) and, although several randomized trials contributed to define the management of extensive and limited stage SCLC, very few data are available for the early stage, possibly resectable, disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
